The Therapeutic Effects of QihaPingchuan Capsule in Combination with Triple Therapy (ICS+LABA+LAMA) on Chronic Obstructive Pulmonary Disease

Objectives

To explore the curative effect of QihaPingchuan Capsule combined with triple therapy [Inhaled Corticosteroid (ICS)+Long-Acting β2 receptor Agonist (LABA)+Long-Acting Anticholinergic drug (LAMA)] on Chronic Obstructive Pulmonary Disease (COPD).

Materials and Methods

A total of 92 patients with COPD admitted to the hospital were enrolled between January 2021 and October 2022. According to the random number table method, they were divided into Group A and Group B, with 46 cases in each group. Group B was given routine symptomatic treatment and triple therapy, while Group A was additionally treated with Qiha Pingchuan Capsules. All were treated for two weeks. The clinical curative effect, scores of TCM syndromes and COPD Assessment Test (CAT), 6-Minute Walk Distance (6MWD), Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), Peak Expiratory Flow (PEF), Partial Pressure of Oxygen (PO₂), partial Pressure of Carbon dioxide (PCO₂), serum C-Reactive Protein (CRP), Interleukin-8 (IL-8) and incidence of adverse reactions were compared between the two groups before and after treatment.

Results

The total response rate of treatment in group A was significantly higher than in group B (89.13% vs. 71.74%, p <0.05). After treatment, TCM syndromes and CAT scores in group A were significantly lower than those in group B and 6MWD was significantly longer than in group B (p <0.05). FCV, FEV1 and PEF in group A were significantly higher than in group B (p <0.05). PO2 in group A was significantly higher than in group B, while PCO2, CRP and IL-8 levels were significantly lower than those in group B (p <0.05). There was no significant difference in the incidence of adverse reactions between group A and group B (15.22% vs. 10.87%, p >0.05).

Conclusion

QihaPingchuan Capsule combined with triple therapy (ICS+LABA+LAMA) can improve the clinical curative effect, effectively relieve clinical symptoms and improve pulmonary function and inflammatory response in COPD patients, with reasonable safety.